ABT · 8-K · 20261021PR066601

Revenue Performance and Mix

ABBOTT LABORATORIES · 2026-10-21 · Importance 64 · Surprise 56 · No source text

Third-quarter 2026 reported sales increased 14.5% year over year to $13.013 billion, while comparable sales increased 7.0%. Diagnostics sales rose 46.7% to $3.305 billion on a reported basis and 6.4% comparably, including Cancer Diagnostics comparable growth of 13.8% driven by Cologuard and precision oncology. Medical Devices sales increased 6.9% to $5.826 billion on a reported basis and 7.8% comparably, led by Electrophysiology growth of 15.0% and Rhythm Management growth of 9.7%. Nutrition sales increased 5.1% to $2.262 billion, while Established Pharmaceuticals sales increased 6.8% to $1.614 billion, with Key Emerging Markets up 9.0% reported and 10.9% comparable.

Key facts

• Worldwide Diagnostics sales increased 46.7 percent on a reported basis and 6.4 percent on a comparable basis in the third quarter source
• Nine months net sales 9M26: $36,770 million, up 11.9% vs 9M25 source
• Third-quarter reported sales growth: 14.5 percent source
• Third-quarter comparable sales growth: 7.0 percent source
• Worldwide Medical Devices sales increased 6.9 percent on a reported basis and 7.8 percent on a comparable basis in the third quarter source
• Total company net sales for 3Q26: $13,013 million source
• Total company net sales for first nine months 2026 (9M26): $36,770 million source
• Worldwide Diagnostics sales for 3Q26: $3,305 million source

Impact estimates